Looking at the trading patterns AGIO is dominated by shorts with brief short covering rallies, and that will not stop until AGIO is able to break through the 50 EMA. Stock is trying hard to break through but always bounces back from the EMA. An event trigger will be needed such a one of the presentations.
If you're looking at the space AGIO is in, and compare performance of these stocks, I'd say risk has been re-priced. Look at PBYI,BLUE,MDVN,CLDX,BMRN; all have been re-priced to similar levels to reflect the high risk build into these stocks, while others CLVS with a more certain outcome performed better. I think we need to see the results from the trials come in for these stocks for any positive movement. Just my two cents...
Now having option expiration behind us I'm real curious about the direction of Agio. Looking at the max pain for Nov OE it's still at 110, which indicates that AGIO may rebound.
Too many folks were invested in BioTech, hence the market needed to maximize profits, meaning shake out longs. Today there is a write up that shorts increased their bets against BioTech, which could mean good news. The markets, labeled as always efficient may need to shake out the shorts for maximizing profits.
Just watch out my little preashitty psycho shorty that your behind is not getting ripped wide open over the next few month. Oh I forgot you're just a psycho having fun, not any money in the market. And that is the last you hear from me; I'm not getting down to your level but once.
Morgan Stanley Selloff Spells Buying Opportunity
Shares have tumbled near 20% since late July but shares look cheap amid strength in wealth-management.
By JOHANNA BENNETT
Oct. 7, 2015 5:25 p.m. ET
Down roughly 20% since late July, Morgan Stanley has been the biggest loser among the four big U.S. investment banks. The stock tumbled with the broader market during its recent selloff. And Morgan, along with other banks, faced further pressure last month after the Federal Reserve decided against raising short-term interest rates.
Is it time to buy? RBC Capital Markets thinks so. Early Wednesday, analyst Fiona Swaffield upgraded Morgan Stanley (ticker: MS ) to Outperform from Sector Perform, while maintaining her $39 price target. She describes the stock’s recent selloff as an “overreaction.” Investors seem to agree as the stock is 1.4% higher to a recent $32.81.
A group of stocks such a biotech down this much shows that this market has been rigged to maximize profits for wallstreet. Biotech are the only place where profits are growing strongly due to innovation. This is crazy!
Prices would sky rock fast
The sinking tide took all ships down even so BioTech is not affected at all by the China problems, etc. Q3 earnings seems to come in strong and GILD will recover and then some.
With the current market storm and China problems, even so BioTech is not affected but the outgoing tide takes down all ships, I'll say that AMGN may only get to 200 by year end.